Does Cosentyx Help Psoriasis?
Cosentyx (secukinumab) treats moderate to severe plaque psoriasis in adults and children 6 years and older who need systemic therapy or phototherapy. It blocks interleukin-17A (IL-17A), a protein driving psoriasis inflammation, reducing plaques, scaling, and itching. Clinical trials show 75-90% of patients achieve at least 75% skin clearance (PASI 75) after 12 weeks, with many reaching near-complete clearance (PASI 90 or 100).[1][2]
How Quickly Does Cosentyx Work for Psoriasis?
Patients often see improvements within 2-4 weeks, with full effects by week 12. In the ERASURE and FIXTURE trials, 82% reached PASI 75 by week 12 on 300 mg doses, compared to 3-9% on placebo. Long-term data shows sustained response over 5 years with maintenance dosing every 4 weeks.[1][3]
Who Qualifies for Cosentyx Psoriasis Treatment?
FDA approves it for moderate-to-severe cases unresponsive to topical treatments, oral systemic drugs, or phototherapy. It's not first-line for mild psoriasis. Dermatologists assess via PASI score, body surface area affected, and quality-of-life impact.[1][4]
Common Side Effects and Risks
Upper respiratory infections occur in 14-20% of patients. Others include diarrhea (4%), oral herpes (2%), and injection-site reactions (3%). Serious risks: increased inflammatory bowel disease flares, rare fungal infections, or hypersensitivity. Screen for tuberculosis before starting; monitor during treatment.[1][5] Pregnancy category B; limited data.
How Does Cosentyx Compare to Other Psoriasis Drugs?
| Drug | Mechanism | PASI 75 Rate (Week 12) | Dosing | Key Notes |
|------|-----------|-------------------------|--------|----------|
| Cosentyx (secukinumab) | IL-17A inhibitor | 75-84% | SubQ weekly x4, then monthly | Fast onset; good for nails/joints |
| Stelara (ustekinumab) | IL-12/23 inhibitor | 67-76% | SubQ every 12 weeks | Fewer infections |
| Tremfya (guselkumab) | IL-23 inhibitor | 73-91% | SubQ every 8 weeks | High clearance rates |
| Skyrizi (risankizumab) | IL-23 inhibitor | 75-88% | SubQ every 12 weeks | Weight-independent dosing |
| Humira (adalimumab) | TNF inhibitor | 71-80% | SubQ every 2 weeks | More infection risk[1][6] |
IL-17/23 inhibitors like Cosentyx often outperform TNFs in head-to-head trials for skin clearance.
Cosentyx for Psoriatic Arthritis Too?
Yes, it treats active psoriatic arthritis (PsA) in adults/children 2+, including those with plaque psoriasis. It reduces joint pain, swelling, and skin symptoms; 70-80% achieve ACR20 response.[1][7]
Cost and Access for Psoriasis Patients
List price is $6,000-$7,000 monthly before rebates. Patient assistance via Novartis covers copays for eligible insured/uninsured. Biosimilars not yet approved in US.[8]
Sources
[1]: Cosentyx Prescribing Information (FDA)
[2]: NEJM: Secukinumab Phase 3 Trials
[3]: JAAD: 5-Year Efficacy
[4]: AAD Guidelines
[5]: Cosentyx Safety Data
[6]: UNCOVER-2/3 Trials Comparison
[7]: FUTURE Trials PsA
[8]: Drugs.com Pricing